< Back to Press

STUDY PRESENTED AT THE AMERICAN DIABETES ASSOCIATION’S 78^TH SCIENTIFIC SESSIONS SHOWS PATIENTS USING CONTOUR^®NEXT ONE SMART METER AND APP REPORTED BETTER UNDERSTANDING AND ENGAGEMENT IN DIABETES MANAGEMENT

Orlando, Florida, United States

This week at the American Diabetes Association 78^th Scientific Sessions, data were presented from a study sponsored by Ascensia Diabetes Care that assessed user experience for the CONTOUR^®NEXT ONE smart meter and app system. The results of this study are featured in three poster presentations that showed that the majority of subjects in the trial responded that the system would provide them with a better understanding of their diabetes and helped them feel more engaged with their diabetes self-management. The American Diabetes Association’s 78^th Scientific Sessions are taking place in Orlando, Florida from June 22-26, 2018.

The results were obtained in a 6-week study^† of 46 insulin-using individuals with diabetes who were using the CONTOUR^®NEXT ONE smart meter and a prototype version of the CONTOUR^®DIABETES app (Release 2). The latest version of the app, which was released in the United States in May 2018, includes the new My Patterns feature, which uses innovative algorithms to more intelligently analyze blood glucose results received from the meter, and delivers personalized meaningful feedback to patients. It is based on the Information, Motivation and Behavioral Skills (IMB) model of health behavior change, that has been applied to diabetes self-management. The IMB model emphasizes the need for actionable information, motivation to act, and behavioral skills for acting effectively, to strengthen self-management of diabetes.

Data presented in the first poster¹ showed that almost all subjects strongly agreed/agreed that using the meter and app system provided them with a better understanding of their disease (98%) and helped them feel more engaged with their diabetes management program (91%). More than three out of four subjects (76%) strongly agreed/agreed that they felt more motivated to adhere to their health care provider's therapy and testing recommendations. In addition, subjects strongly agreed/agreed that the “My Patterns” pattern recognition feature was helpful in managing their diabetes (73%).

Fructosamine levels and HbA1c were also measured during the study. The predetermined analysis presented in the second poster² that was part of the study protocol showed that mean fructosamine levels, which correlate to blood glucose levels over the prior 2-3 weeks, decreased significantly from the beginning to the end of the study (P = 0.0076). The average change in HbA1c for subjects was not significant between their two study visits.

Additional post hoc analyses in the third poster³ revealed a significant decrease in the number of above-target (“high”) blood glucose measurements at the end of the study compared to the beginning (P <0.0003). The average number of blood glucose tests performed per week increased significantly over the course of the study (P <0.0001), indicating the potential effects of using the system on encouraging patient adherence to treatment and better control of blood glucose levels. A consistent decrease in the average blood glucose values for fasting, before meal, and after meal was also observed, but this was not statistically significant.

Further information and results from these studies can be found in the posters, which will be displayed as below:

User Experience with a New Smartphone Application for Blood Glucose Monitoring (BGM) in an Information-Motivation-Behavioral Skills (IMB) Model Study (Fisher W et al.)
Monday Jun 25, 2018   12:00 - 1:00 PM  Poster #692P

The New Smartphone Application for Blood Glucose Monitoring (BGM) With Information-Motivation-Behavioral Skills (IMB) Model Study (Pardo S et al.)
Saturday June 23, 2018   11:30-12:30 PM   Poster #924P

Use of the New Smartphone Application for Blood Glucose Monitoring (BGM) With Information-Motivation-Behavioral Skills (IMB) Model Has an Impact on Diabetes Control Parameters (Pardo S et al.)
Saturday June 23, 2018   11:30-12:30 PM   Poster #925P

_{^†This study was sponsored by Ascensia Diabetes Care.}

ENDS

About Ascensia Diabetes Care

Ascensia Diabetes Care is a global specialist diabetes care company, dedicated to helping people living with diabetes. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. We use our innovation and specialist expertise in diabetes to develop high quality solutions and tools that make a positive, daily difference for people with diabetes.

Home to the world renowned CONTOUR^® portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.

Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Ascensia Diabetes Care has around 1,700 employees and operations in 31 countries.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com.

© 2016 Ascensia Diabetes Care. Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care. The Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license. All product names and trademarks are the property of their respective owners.

For more information, please contact:
Joseph Delahunty, VP, Global Head of Communications
Ascensia Diabetes Care
E-mail: joseph.delahunty@ascensia.com  
Phone: +41 61 560 8760

References

1. Fisher W et al. Poster presented at American Diabetes Association 78th Scientific Sessions (Poster #692P)

2. Pardo S et al. Poster presented at American Diabetes Association 78th Scientific Sessions (Poster #924P)

3. Pardo S et al. Poster presented at American Diabetes Association 78th Scientific Sessions (Poster #925P)